Long-Term Cardiovascular Toxicity of Immunotherapy: Too Important to Ignore
Andrea Camerini(Ospedale Versilia), Fabrizio Oliva(Associazione Nazionale Medici Cardiologi Ospedalieri), Attilio Iacovoni(Ospedale Papa Giovanni XXIII), Luigi Tarantini(Santa Maria Nuova Hospital), Giuseppina Gallucci, Alessandra Greco(St. Catherine University), Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Claudio Bilato(AULSS 2 Marca Trevigiana), Furio Colivicchi(Ospedale San Filippo Neri), Giovanna Geraci(Ospedale Vincenzo Cervello), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Stefano Oliva(Istituto Tumori Bari), Nicola Maurea(Cancer Institute (WIA)), Carmine Riccio(Ospedale Sant'Anna), Andrea Tedeschi(Guglielmo da Saliceto Hospital), Maria Laura Canale(Ospedale Versilia), Alessandro Navazio(Presidio Ospedaliero), Marzia De Biasio, Massimo Grimaldi(Ospedale Generale Regionale Francesco Miulli)
Cited by 1
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prevalence and Prognostic Impact of Non-Cardiac Co-Morbidities in Heart Failure Outpatients with Preserved and Reduced Ejection Fraction: A Community-Based Study
|European Journal of Heart Failure|2018|174
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
|Critical Reviews in Oncology/Hematology|2019|164
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116